Biophytis announces the successful completion of a €2,6 million private placement
- Capital increase of a total amount of approximately €2,6 million in gross proceeds by issuing 4,307,614 new shares, each with one share warrant attached, at €0,26 per unit, and 5,692,308 pre-funded warrants, each with one share warrant attached, at €0,25 per pre-funded unit;
- Gross proceeds include €2 million from Armistice, and approximately €0,6 million from a limited number of other qualified investors.
- Settlement-delivery of the new shares and share warrants expected on March 28, 2025.
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN AND SOUTH AFRICA
Biophytis announces today the successful completion of a capital increase of a total gross amount of €2,6 million subscribed by a limited number of investors, including Armistice (for €2M) and qualified investors (for €0,6M) (the “Private Placement”).
Stanislas Veillet, CEO of Biophytis, stated: “We are pleased with the strong interest shown by investors in this private placement, which underscores the confidence in our strategy and the significant potential of our clinical programs. We believe that this fundraising will allow us to further accelerate the development of BIO101 through ambitious clinical programs, in obesity over the short-term, and also in sarcopenia. Our team is fully committed to advancing research with the aim of improving patients’ lives while addressing major unmet medical needs.”
The Private Placement is not subject to a prospectus requiring approval from the French Financial Market Authority (Autorité des Marchés Financiers – the “AMF”).
